var data={"title":"Clofarabine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clofarabine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5922?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clofarabine-drug-information\" class=\"drug drug_general\">see &quot;Clofarabine: Drug information&quot;</a> and <a href=\"topic.htm?path=clofarabine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clofarabine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152997\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Clolar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16057714\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Clolar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046474\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite (Purine Antagonist)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046467\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=clofarabine-drug-information\" class=\"drug drug_general\">see &quot;Clofarabine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Pediatric: <b>Note:</b> Consider prophylactic corticosteroids (hydrocortisone 100 mg/m<sup>2</sup> on days 1 to 3) to prevent signs/symptoms of capillary leak syndrome or systemic inflammatory response syndrome (SIRS). Provide IV hydration, antihyperuricemic therapy, and alkalinize the urine to reduce the risk of tumor lysis syndrome/hyperuricemia. Calculate body surface area (BSA) prior to each cycle utilizing actual body weight. Clofarabine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <b>Acute lymphocytic leukemia (ALL), relapsed or refractory: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <i>Monotherapy:</i> Children and Adolescents: IV infusion: 52 mg/m<sup>2</sup>/day once daily for days 1 to 5 of each cycle; repeat cycle every 2 to 6 weeks following recovery or return to baseline organ function; subsequent cycles should begin no sooner than 14 days from the start of the previous cycle and when ANC &ge;750/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">\n      <i>Combination therapy:</i> Limited data available: IV Infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;\">Infants: Dosing regimens variable with very limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">Weight-directed dosing: 1.33 mg/kg/day for 5 days in combination with cyclophosphamide and etoposide (O&rsquo;Connor 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;margin-top:0em;\">BSA-directed dosing: 40 mg/m<sup>2</sup>/day for 5 days in combination with cyclophosphamide and etoposide (Inaba 2012); and with topotecan, vinorelbine, thiotepa (TVTC regimen), and dexamethasone in a Phase I trial (Steinherz 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: Usual dose: 40 mg/m<sup>2</sup>/day for 5 days in combination with cyclophosphamide and etoposide has been most frequently studied (Hijiya 2011; Hijiya 2012; Inaba 2012; Locatelli 2009; O&rsquo;Connor 2011); and with topotecan, vinorelbine, thiotepa (TVTC regimen), and dexamethasone in a Phase I trial (Steinherz 2010). In one trial, the protocol included 5 days of clofarabine therapy during induction and 4 days of therapy for consolidation; this study was also amended to exclude patients with prior hematopoietic stem cell transplantation due to a high incidence of veno-occlusive disease (Hijiya 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia (AML), relapsed or refractory:</b> Limited data available: Children and Adolescents: IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Monotherapy:</i> 52 mg/m<sup>2</sup>/day once daily for days 1 to 5 of each cycle; repeat cycle every 2 to 6 weeks for up to 12 cycles following recovery or return to baseline organ function; subsequent cycles should begin no sooner than 14 days from the start of the previous cycle and when ANC &ge;750/mm<sup>3</sup>; the trial did not have minimum exclusion age (patient age &le;21 years at time of diagnosis); the youngest patient was 2 years of age (Jeha 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Combination therapy:</i> 40 mg/m<sup>2</sup>/day once daily for days 1 to 5 of each cycle in combination with cyclophosphamide and etoposide (Inaba 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Langerhans cell histiocytosis, refractory:</b> Limited data available: Children and Adolescents: IV: 25 mg/m<sup>2</sup>/day days 1 through 5; repeat every 28 days for 2 to 8 cycles (Simko 2014). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Consider prophylactic corticosteroids (hydrocortisone 100 mg/m<sup>2</sup> on days 1 to 3) to prevent signs/symptoms of capillary leak syndrome or systemic inflammatory response syndrome (SIRS), and hydration and antihyperuricemic therapy (to reduce the risk of tumor lysis syndrome/hyperuricemia). Calculate body surface area (BSA) prior to each cycle, utilizing actual body weight. Clofarabine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Basch 2011; Roila 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphocytic leukemia (ALL), relapsed or refractory:</b> Patients &le;21 years: IV infusion: 52 mg/m<sup>2</sup>/day once daily for days 1 to 5 of each cycle; repeat cycle every 2 to 6 weeks following recovery or return to baseline organ function; subsequent cycles should begin no sooner than 14 days from the start of the previous cycle and when ANC &ge;750/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> Children, Adolescents, and Adults &le;21 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic toxicity: ANC &lt;500/mm<sup>3</sup> lasting &ge;4 weeks: Reduce clofarabine dose by 25% for next cycle </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nonhematologic toxicity: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Clinically significant infection:</i> Withhold treatment until infection is under control, then restart clofarabine at full dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Grade 3 toxicity, excluding infection, nausea, and vomiting, and transient elevations in transaminases and bilirubin:</i> Withhold treatment; may reinitiate clofarabine with a 25% dose reduction with resolution or return to baseline </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Grade &ge;3 increase in creatinine or bilirubin:</i> Discontinue clofarabine; may reinitiate with 25% dosage reduction when creatinine or bilirubin return to baseline and patient is stable; administer antihyperuricemic therapy for elevated uric acid</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Grade 4 toxicity (noninfectious):</i> Discontinue clofarabine treatment </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Capillary leak or systemic inflammatory response syndrome (SIRS) early signs/symptoms (eg, hypotension, tachycardia, tachypnea, pulmonary edema):</i> Discontinue clofarabine; institute supportive measures. May consider reinitiating with a 25% dose-reduction after patient is stable and after organ function recovers to baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dermatologic toxicity:</i> Exfoliative or bullous rash, or suspected Stevens-Johnson syndrome or toxic epidermal necrolysis: Discontinue clofarabine. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Hypotension (during the 5 days of infusion</i>): Discontinue clofarabine. If hypotension is transient and resolves (without pharmacologic intervention), some have suggested that may reinitiate with 25% dosage reduction (Clolar Canadian prescribing information 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for renal impairment:</b> Children, Adolescents, and Adults &le;21 years: Clofarabine undergoes renal elimination and exposure is increased as creatinine clearance decreases (Bonate 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Baseline renal impairment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;60 mL/minute: No dosage adjustment recommended</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 60 mL/minute: Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; use with caution (insufficient evidence)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Renal toxicity during therapy:</i> Grade 3 or higher increase in serum creatinine: Discontinue clofarabine; may reinitiate with a 25% dose reduction after patient is stable and organ function recovers to baseline</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for hepatic impairment:</b> Children, Adolescents, and Adults &le;21 years: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Baseline hepatic impairment:</i> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hepatotoxicity during therapy:</i> Grade 3 or higher increase in bilirubin: Discontinue clofarabine; may reinitiate with a 25% dose reduction after patient is stable and organ function recovers to baseline.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152978\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clolar: 1 mg/mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152966\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046477\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: IV infusion: Administer by IV infusion over 2 hours per the manufacturer's labeling and in most trials; a few trials have infused over 1 hour (Federl 2005; Jeha 2004; Kantarian 2003). An inline filter is not needed for administration. Do not administer with any other medications through the same intravenous line. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130933\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).   </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152992\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Solutions diluted for infusion in D<sub>5</sub>W or NS may be stored for up to 24 hours at room temperature (use within 24 hours of preparation).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046476\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) after at least two prior treatment regimens (FDA approved in ages 1 to 21 years); has also been used for the treatment of acute myelogenous leukemia (AML) and refractory Langerhans cell histiocytosis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401601\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Clofarabine may be confused with cladribine, clevidipine, cytarabine, nelarabine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F153018\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions include off-label use in the treatment of AML.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Capillary leak syndrome, edema, flushing, hypertension, hypotension, pericardial effusion, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, anxiety, chills, drowsiness, fatigue, headache, irritability, lethargy, mental status changes, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Cellulitis, erythema, palmar-plantar erythrodysesthesia, pruritic rash, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, gingival bleeding, mucosal inflammation, nausea, oral candidiasis, pancreatitis, pseudomembranous colitis, rectal pain, stomatitis, typhlitis, upper abdominal pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, febrile neutropenia (less common in grade 4), leukopenia, lymphocytopenia, neutropenia, oral mucosal petechiae, petechia (less common in grade 3), thrombocytopenia, tumor lysis syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hyperbilirubinemia, increased bilirubin, increased serum ALT, increased serum AST, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Bacteremia, candidiasis, herpes simplex infection, herpes zoster, infection (includes bacterial, fungal, and viral), influenza, sepsis (including septic shock), sepsis syndrome, staphylococcal bacteremia, staphylococcal sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Catheter infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain, myalgia, ostealgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute renal failure, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, epistaxis, pleural effusion, pneumonia, pulmonary edema, respiratory distress, sinusitis, tachypnea, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Enterocolitis (occurs more frequently within 30 days of treatment and with combination chemotherapy), exfoliative dermatitis, gastrointestinal hemorrhage, hallucination (Jeha 2006), hepatic failure, hepatitis, hepatomegaly (Jeha 2006), hypokalemia (Jeha 2006), hyponatremia, hypophosphatemia, increased right ventricular pressure (Jeha 2006), left ventricular systolic dysfunction (Jeha 2006), major hemorrhage (including cerebral and pulmonary; majority of cases associated with thrombocytopenia), Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152983\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to clofarabine or any component of the formulation; symptomatic CNS involvement; history of serious heart, liver, kidney, or pancreas disease; severe hepatic impairment (AST and/or ALT &gt;5 x ULN, and/or bilirubin &gt;3 x ULN); severe renal impairment (CrCl &lt;30 mL/minute)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152968\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Dose-dependent, reversible myelosuppression (neutropenia, thrombocytopenia, and anemia) is common; may be severe and prolonged. Monitor blood counts and platelets. May be at increased risk for infection due to neutropenia. Monitor for signs and symptoms of infection and treat promptly if infection develops; may require discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Capillary leak syndrome/systemic inflammatory response syndrome (SIRS): Cytokine release syndrome (eg, tachypnea, tachycardia, hypotension, pulmonary edema) may develop into capillary leak syndrome/SIRS, and organ dysfunction; immediately discontinue with signs/symptoms of SIRS or capillary leak syndrome (rapid-onset respiratory distress, hypotension, pleural/pericardial effusion, and multiorgan failure) and manage appropriately. Consider supportive treatment with diuretics, corticosteroids, and/or albumin. Prophylactic corticosteroids may prevent or diminish the signs/symptoms of cytokine release. May require dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Serious and fatal cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported. Discontinue clofarabine for exfoliative or bullous rash, or if SJS or TEN are suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Clofarabine is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016). Serious and fatal enterocolitis (including neutropenic colitis, cecitis, and <i>C. difficile</i> colitis) has been reported, usually occurring within 30 days of treatment, and when used in combination with other chemotherapy. May lead to necrosis, perforation, hemorrhage or sepsis complications. Monitor for signs/symptoms of enterocolitis and manage promptly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Serious and fatal hemorrhages (including cerebral, gastrointestinal, and pulmonary hemorrhage) have occurred, usually associated with thrombocytopenia. Monitor and manage coagulation parameters.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Transaminases and bilirubin may be increased during treatment; hepatitis and hepatic failure have been reported. Transaminase elevations generally occur within 10 days of administration and persist for &le;15 days. In some cases, hepatotoxicity was severe and fatal. The risk for hepatotoxicity, including hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]), is increased in patients who have previously undergone a hematopoietic stem cell transplant; discontinue if SOS is suspected. Avoid the concomitant use of drugs that may cause hepatotoxicity. Monitor liver function closely; discontinue immediately for grade &ge; 3 elevations in hepatic enzymes and/or bilirubin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Monitor blood pressure during 5 days of treatment; discontinue if hypotension develops. Monitor if on concurrent medications known to affect blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: The risk for infections, including opportunistic infection or sepsis (may be severe or fatal), is increased due to prolonged neutropenia and immunocompromised state. Monitor for signs and symptoms of infection and treat promptly if infection develops; may require therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: Elevated creatinine, acute renal failure, and hematuria were observed in clinical studies. Infection, sepsis, or tumor lysis syndrome may cause an increased risk of renal toxicity in patients receiving clofarabine. Monitor renal function closely; may require dosage reduction or therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome/hyperuricemia: Tumor lysis syndrome may occur as a consequence of leukemia treatment, including treatment with clofarabine, usually occurring in the first treatment cycle. May lead to life-threatening acute renal failure; adequate hydration and prophylactic antihyperuricemic therapy throughout treatment will reduce the risk/effects of tumor lysis syndrome; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: A pharmacokinetic study demonstrated that systemic exposure increases as creatinine clearance decreases (CrCl &lt;60 mL/minute) (Bonate 2011). Dosage reduction required for CrCl 30 to 60 mL/minute; use with caution in patients with CrCl &lt;30 mL/minute (has not been studied). Minimize the use of drugs known to cause renal toxicity during the 5-day treatment period.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299065\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152972\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12924&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152974\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152986\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. May cause fetal harm if administered to a pregnant woman. Women of childbearing potential should avoid becoming pregnant during therapy. All patients should use effective contraception to prevent pregnancy during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1046473\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets (daily during treatment, then 1-2 times weekly or as necessary); liver and kidney function (during 5 days of clofarabine administration); blood pressure, cardiac function, and respiratory status during infusion; signs and symptoms of tumor lysis syndrome, infection, and cytokine release syndrome (tachypnea, tachycardia, hypotension, pulmonary edema); hydration status</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152967\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Clofarabine, a purine (deoxyadenosine) nucleoside analog, is metabolized to clofarabine 5'-triphosphate. Clofarabine 5'-triphosphate decreases cell replication and repair as well as causing cell death. To decrease cell replication and repair, clofarabine 5'-triphosphate competes with deoxyadenosine triphosphate for the enzymes ribonucleotide reductase and DNA polymerase. Cell replication is decreased when clofarabine 5'-triphosphate inhibits ribonucleotide reductase from reacting with deoxyadenosine triphosphate to produce deoxynucleotide triphosphate which is needed for DNA synthesis. Cell replication is also decreased when clofarabine 5'-triphosphate competes with DNA polymerase for incorporation into the DNA chain; when done during the repair process, cell repair is affected. To cause cell death, clofarabine 5'-triphosphate alters the mitochondrial membrane by releasing proteins, an inducing factor and cytochrome C.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F152982\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Decreased with increasing age, based on pharmacokinetic simulations: 5.8 L/kg (3 years old); 3.1 L/kg (30 years old); 2.7 L/kg (82 years old) (Bonate 2011); Children and Adolescents 2 to 19 years: 172 L/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 47%, primarily to albumin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Intracellulary by deoxycytidine kinase and mono- and diphosphokinases to active metabolite clofarabine 5&prime;-triphosphate; limited hepatic metabolism (0.2%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Children and Adolescents 2 to 19 years: 5.2 hours; Children and Adults: 7 hours; may be prolonged in in the elderly and in patients with renal impairment  (Bonate, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (49% to 60%, as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323073\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clofarabine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (20 mL): $3,166.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Clolar Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (20 mL): $3,521.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038584\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Clofazic (AR, CL, EC, PE);</li>\n      <li>Clolar (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Evoltra (AT, AU, BE, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HK, HR, HU, IE, IL, IT, JP, KR, LB, LT, LU, LV, MT, MY, NL, NO, NZ, PL, PT, RO, SE, SG, SI, SK, TH, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonate PL, Cunningham CC, Gaynon P, et al, &ldquo;Population Pharmacokinetics of Clofarabine and its Metabolite 6-Ketoclofarabine in Adult and Pediatric Patients With Cancer,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2011, 67(4):875-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/20582417/pubmed\" target=\"_blank\" id=\"20582417\">20582417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clolar (clofarabine) [prescribing information]. Cambridge, MA: Genzyme Corporation; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clolar (clofarabine) [Canadian prescribing information]. Laval, Quebec: sanofi-aventis Canada Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Federl S, Gandhi V, O&rsquo;Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. <i>Blood</i>. 2005; 105:940-947.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/15486072/pubmed\" target=\"_blank\" id=\"15486072\">15486072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hijiya N, Barry E, Arceci R. Clofarabine in pediatric acute leukemia: current findings and issues. <i>Pediatr Blood Cancer</i>. 2012;59:417-422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/22354543/pubmed\" target=\"_blank\" id=\"22354543\">22354543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. <i>Blood</i>. 2001;118 6043-6049.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/21967976/pubmed\" target=\"_blank\" id=\"21967976\">21967976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inaba H, Bhojwani D, Pauley JL, et.al. Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. <i>Br J Haematol</i>. 2012;156(2):275-279.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/21883141/pubmed\" target=\"_blank\" id=\"21883141\">21883141</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeha S, Gandhi V, Chan KW, et al, &ldquo;Clofarabine, a Novel Nucleoside Analog, Is Active in Pediatric Patients With Advanced Leukemia,&rdquo; <i>Blood</i>, 2004, 103(3):784-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/14551141/pubmed\" target=\"_blank\" id=\"14551141\">14551141</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeha S, Gaynon PS, Razzouk BI, et al, &quot;Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia,&quot; <i>J Clin Oncol</i>, 2006, 24(12):1917-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/16622268/pubmed\" target=\"_blank\" id=\"16622268\">16622268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeha S, Razzouk B, Rytting M, et.al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. <i>J Clin Oncol</i>. 2009;27:4392-4397. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/19652076/pubmed\" target=\"_blank\" id=\"19652076\">19652076</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian H, Gandhi V, Cortes J, et al, &quot;Phase 2 Clinical and Pharmacologic Study of Clofarabine in Patients With Refractory or Relapsed Acute Leukemia,&quot; <i>Blood</i>, 2003, 102(7):2379-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/12791647/pubmed\" target=\"_blank\" id=\"12791647\">12791647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Locatelli F, Testi AM, Bernardo ME, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. <i>British Journal of Haematology</i>. 2009;147:371-378.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/19747360/pubmed\" target=\"_blank\" id=\"19747360\">19747360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O&rsquo;Connor D, Sibson K, Caswell M, et al. Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. <i>British Journal of Haematology</i>. 2011;154:482-485.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/21689087/pubmed\" target=\"_blank\" id=\"21689087\">21689087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. <i>Pediatr Blood Cancer</i>. 2014;61(3):479-487.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/24106153 /pubmed\" target=\"_blank\" id=\"24106153 \">24106153 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steinherz PG, Shukla N, Kobos R, et al. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa and vinorelbine for patients with relapsed or refractory leukemia. <i>Pediatr Blood Cancer</i>. 2010;54:687-693. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofarabine-pediatric-drug-information/abstract-text/20205253/pubmed\" target=\"_blank\" id=\"20205253\">20205253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12924 Version 135.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F152997\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F16057714\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1046474\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1046467\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F152978\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F152966\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1046477\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130933\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F152992\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1046476\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401601\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F153018\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F152983\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F152968\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299065\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F152972\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F152974\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F152986\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1046473\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F152967\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F152982\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323073\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038584\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12924|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clofarabine-drug-information\" class=\"drug drug_general\">Clofarabine: Drug information</a></li><li><a href=\"topic.htm?path=clofarabine-patient-drug-information\" class=\"drug drug_patient\">Clofarabine: Patient drug information</a></li></ul></div></div>","javascript":null}